Plain-English translation of NCT05997056 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called for people with neuroendocrine tumors — rare, slow-growing cancers that can start in the gut, lungs, or pancreas. The study will enroll 21 people to see how well this treatment works and how safe it is. Researchers want to understand whether the medication can slow or stop tumor growth in people who haven't previously tried this type of drug.
Neuroendocrine tumors are difficult to treat, and many patients eventually need new options when other treatments stop working or don't work well enough. This trial exists to see if this medication could offer another effective choice for patients who haven't had the chance to try this type of therapy before.
If you join this trial, you will receive the new medication as part of your cancer treatment at one of several hospitals across the country. The study team will monitor you with regular clinic visits, blood tests, and imaging scans to see how well the medication is working and check for any side effects. Your participation will involve visits to the study center at regular intervals, and the study team will ask you to report any symptoms or concerns you experience while taking the medication.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States